Method of treating patients with hepatorenal syndrome type 1
US-2024366710-A1 · Nov 7, 2024 · US
Method of treatment for neutropenia using stable formulations of recombinant human albumin-human granulocyte colony stimulating factor
US8993519B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8993519-B2 |
| Application number | US-201213660915-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 25, 2012 |
| Priority date | Jan 16, 2009 |
| Publication date | Mar 31, 2015 |
| Grant date | Mar 31, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Described herein are compositions and methods for treating, preventing and ameliorating diseases and conditions characterized by a lower than normal white blood cell count, such as leukopenia and neutropenia. The compositions and methods include recombinant human albumin-human granulocyte colony stimulating factor. Pharmaceutical formulations including the recombinant fusion protein, and methods of making such formulations are also described.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating or preventing neutropenia in a human comprising administering to a human exhibiting neutropenia or at risk of developing neutropenia a pharmaceutical composition comprising recombinant human albumin-human granulocyte colony stimulating factor, and at least one pharmaceutically acceptable carrier, wherein the composition has a pH of between 4 and 6.4, wherein the concentration of recombinant human albumin-human granulocyte colony stimulati…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8993519B2 cover?
- Described herein are compositions and methods for treating, preventing and ameliorating diseases and conditions characterized by a lower than normal white blood cell count, such as leukopenia and neutropenia. The compositions and methods include recombinant human albumin-human granulocyte colony stimulating factor. Pharmaceutical formulations including the recombinant fusion protein, and method…
- Who is the assignee on this patent?
- Teva Pharma
- What technology area does this patent fall under?
- Primary CPC classification A61K38/38. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 31 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).